Teva- Sanofi showcase best-in-class TL1A potential, without a biomarker

A third TL1A antagonist has excelled in a Phase II inflammatory bowel disease trial, reinforcing the class’ promise in the challenging indication and setting it up for a fiercely competitive commercial landscape.

Despite the availability of compelling biomarker signatures for predicting responses to the drug class, the new data suggest once again that all-comer efficacy signals may be strong enough to forge ahead without restricting patient populations — raising the perennial question of what it’s going to take to incentivize precision medicine...